Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia

British Journal of Haematology

Volumn 123, Issue 4, 2003, Pages 730-737

  Voskaridou, Ersi ^a   Terpos, Evangelos ^b,c   Spina, Giovanna ^a   Palermos, John ^c   Rahemtulla, Amin ^b   Loutradi, Aphroditi ^a   Loukopoulos, Dimitris ^d  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c General Air Force Hospital   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bone markers; Osteoporosis; Osteoprotegerin; Pamidronate; Thalassaemia

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BETA THALASSEMIA; BIOLOGICAL MONITORING; BONE DENSITY; BONE MINERAL; BONE REMODELING; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; MALE; MEASUREMENT; OSTEOCLAST; OSTEOPOROSIS; PATIENT; PRIORITY JOURNAL;

ACID PHOSPHATASE; ADULT; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; BONE DENSITY; CARRIER PROTEINS; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOPROTEINS; HUMANS; ISOENZYMES; LUMBAR VERTEBRAE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC;

EID: 0344530239     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04657.x     Document Type: Article

References (23)

1. Anapliotou, M.L., Kastanias, I.T., Psara, P., Evangelou, E.A., Liparaki, M. & Dimitriou, P. (1995) The contribution of hypogonadism to the develoment of osteoporosis in thalassemia major: new therapeutic approaches. Clinical Endocrinology, 42, 279-287.
2. Boutsen, Y., Jamart, J., Esselinckx, W. & Devogelaer, J.P. (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone and Mineral Research, 16, 104-112.
3. Brown, J.P. & Josse, R.G. (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Canadian Medical Association Journal, 167(10 Suppl.), S1-S34.
4. Brumsen, C., Papapoulos, S.E., Lips, P., Geelhoed-Duijvestijn, P.H., Hamdy, N.A., Landman, J.O., McCloskey, E.V., Netelenbos, J.C., Pauwels, E.K., Roos, J.C., Valentijn, R.M. & Zwinderman, A.H. (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. Journal of Bone and Mineral Research, 17, 1057-1064.
5. Chesnut, C.H. 3rd & Rose, C.J. (2001) Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. Journal of Bone and Mineral Research, 16, 2163-2172.
6. Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W.J., Lacey, D.L. & Riggs, B.L. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. Journal of Clinical Investigation, 111, 1221-1230.
7. Fleisch, H. (1995) Bisphosphonates-preclinical. In: Bisphosphonates in Bone Disease. From the Laboratory to the Patient, 4th edn (ed. by H. Fleisch), p. 57 Academic Press, San Diego, CA, USA.
8. Halleen, J.M., Alatalo, S.L., Suominen, H., Cheng, S., Janckila, A.J. & Vaananen, H.K. (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. Journal of Bone and Mineral Research, 15, 1337-1345.
9. Haynes, D.R., Crotti, T.N., Loric, M., Bain, G.I., Atkins, G.J. & Findlay, D.M. (2001) Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford), 40, 623-630.
10. Horowitz, M.C., Xi, Y., Wilson, K. & Kacena, M.A. (2001) Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine and Growth Factor Reviews, 12, 9-18.
11. Kim, Y.H., Kim, G.S. & Jeong-Hwa, B. (2002) Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Experimental and Molecular Medicine, 34, 145-151.
12. Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A.J ., Van, G., Itie, A., Khoo. W., Wakeham, A., Dunstan, C.R., Lacey, D.L., Mak, T.W., Boyle, W.J. & Penninger, J.M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, 315-323.
13. Lasco, A., Morabito, N., Gaudio, A., Buemi, M., Wasniewska, M. & Frisina, N. (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporosis International, 12, 570-575.
14. Looker, A.C., Bauer, D.C., Chesnut, C.H. 3rd, Gundberg, C.M., Hochberg, M.C., Klee, G., Kleerekoper, M., Watts, N.B. & Bell N.H. (2000) Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporosis International, 11, 467-480.
15. Meunier, P.J., Delmas, P.D., Eastell, R., McClung, M.R., Papapoulos, S., Rizzoli, R., Seeman, E. & Wasnich RD. (1999) Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clinical Therapeutics, 21, 1025-1044.
16. Morabito, N., Lasco, A., Gaudio, A., Crisafulli, A., Di Pietro, C., Meo, A. & Frisina, N. (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis International, 13, 644-649.
17. Perrotta, S., Cappellini, M.D., Bertoldo, F., Servedio, V., Iolascon, G., D'Agruma, L., Gasparini, P., Siciliani, M.C. & Iolascon, A. (2000) Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. British Journal of Haematology, 111, 461-466.
18. Terpos, E., Viniou, N., de la Fuente, J., Meletis, J., Voskaridou, E., Karkantaris, C., Vaiopoulos, G., Palermos, J., Yataganas, X., Goldman, J.M. & Rahemtulla, A. (2003a) Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta2-microglobulin in multiple myeloma. European Journal of Haematology, 70, 34-42.
19. Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J.M. & Rahemtulla, A (2003b) Soluble receptor activator of nuclear factor {kappa}B ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood, 102, 1064-1069.
20. Viereck, V., Emons, G., Lauck, V., Frosch, K.H., Blaschke, S., Grundker, C. & Hofbauer, L.C. (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochemical and Biophysical Research Communications, 291, 680-686.
21. Voskaridou, E., Kyrtsonis, M.C., Terpos, E., Skordili, M., Theodoropoulos, I., Bergele, A., Diamanti, E., Kalovidouris, A., Loutradi, A. & Loukopoulos, D. (2001) Bone resorption is increased in young adults with thalassaemia major. British Journal of Haematology, 112, 36-41.
22. Wonke, B. (1998) Bone disease in β-thalassaemia major. British Journal of Haematology, 103, 897-901.
23. Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K. & Yamada, Y. (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor; increased serum concentrations in post-menopausal women with osteoporosis. Journal of Bone and Mineral Research, 14, 518-527.